Osimertinib, a Third‐generation EGFR Tyrosine Kinase Inhibitor: A Retrospective Multicenter Study of Its Real‐world Efficacy and Safety in Advanced/Recurrent Non‐small Cell Lung Carcinoma
Thoracic Cancer - Australia
doi 10.1111/1759-7714.13378
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2020
Authors
Publisher
Wiley